DEBRA FELL: Open Payments
NPI 1326025610 · SNOW HILL, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,021 in 58 payments from 20 companies in 2025. Trend: 2023 $1,763 · 2024 $915 · 2025 $1,021
Food & beverage: $1,021
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $255 |
| Novo Nordisk Inc | 6 | $95 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $88 |
| Amgen Inc. | 5 | $77 |
| GlaxoSmithKline, LLC. | 5 | $76 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $61 |
| Lilly USA, LLC | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 2 | $57 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Novartis Pharmaceuticals Corporation | 2 | $34 |
Products named: VRAYLAR, CAPLYTA, TRELEGY ELLIPTA, REXULTI, UBRELVY, XIFAXAN, OTEZLA, ZEPBOUND.
Industry payments across NC — which companies pay providers there.
